Head-To-Head Survey: Pharmaxis (OTCMKTS:PXSLY) & Northwest Biotherapeutics (OTCMKTS:NWBO)

Northwest Biotherapeutics (OTCMKTS:NWBO) and Pharmaxis (OTCMKTS:PXSLY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Profitability

This table compares Northwest Biotherapeutics and Pharmaxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-5,258.91%	N/A	-241.52%
Pharmaxis	N/A	N/A	N/A

Risk & Volatility

Northwest Biotherapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, Pharmaxis has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Northwest Biotherapeutics shares are held by institutional investors. 8.7% of Northwest Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Northwest Biotherapeutics and Pharmaxis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northwest Biotherapeutics	0	0	0	0	N/A
Pharmaxis	0	0	0	0	N/A

Valuation and Earnings

This table compares Northwest Biotherapeutics and Pharmaxis’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.93 million	274.56	-$62.60 million	($0.07)	-6.17
Pharmaxis	$8.75 million	3.03	-$9.36 million	N/A	N/A

Pharmaxis has higher revenue and earnings than Northwest Biotherapeutics.

Summary

Pharmaxis beats Northwest Biotherapeutics on 5 of the 8 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.